<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

Prostate Cancer PDX Models

Suitable preclinical models such as patient-derived xenografts (PDX) are needed to evaluate drugs specifically targeting prostate cancer and have historically been difficult to generate due to the benign nature of this disease and the difficulty in propagating the model. Despite these challenges, Crown Bioscience offers a collection of prostate cancer PDX models featuring tumor material diagnosed based on operative pathology and immunohistochemistry (IHC) focused on prostate specific markers e.g. PSA and androgen receptor expression. More

PDX offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials. Crown Bioscience's HuPrime® PDX models are well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.

MODEL NUMBER CANCER TYPE CANCER SUBTYPE DESCRIPTION # per page
PR6511 Prostate Cancer CRPC Castrate-resistant prostate cancer (CRPC); Recurrent chromosomal abnormalities included losses on chromosomes10q (includingPTEN and MXI1), 12p, 13q (including Rb1), 17p (including TP53), 18q, 3Mb deletion between ERG and TMPRSS2 on Ch21, 6q, and 9q. Gains included the q-arm of X,which was confirmed by PCR for ARTMPRSS-ETS fusion. CLICK TO VIEW
PR6512 Prostate Cancer CRPC Castrate-resistant prostate cancer (CRPC). CLICK TO VIEW

Sorry, no posts matched your criteria.

Create Account to View All Model Data

Already Registered? Login